Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02276885 · ClinicalTrials.gov registry record · NA
Prone Partial Breast Irradiation (PBI): a Prospective Randomized Trial
A NA study of Breast Cancer, sponsored by NYU Langone Health.
- Active
- Registry status
- NA
- Development phase
- 284
- Enrollment target
- 1
- Study location
NCT02276885: Active NA study of Breast Cancer, sponsored by NYU Langone Health.
NCT02276885 is a NA study of Breast Cancer that is active but no longer recruiting, run by NYU Langone Health. The registered enrollment target is 284 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (90% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02276885, a NA study of Breast Cancer, is active but no longer recruiting, sponsored by NYU Langone Health.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 284 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to test whether a radiotherapy regimen of 8 GY x 3 days over 5 days (every other day) is as safe (well-tolerated) and effective as 6 Gy x 5 over five consecutive days
Conditions Studied
Interventions
- RADIATION PBI Radiotherapy 6 Gy
- RADIATION PBI Radiotherapy 8 Gy
Study Locations (1)
New York
- NYU Langone Medical Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 284 participants |
| Start Date | 2014-10-28 |
| Est. Completion | 2026-12-07 |
| Phase | NA |
What the registry record for NCT02276885 still lists
NCT02276885 is an interventional study that assigns participants to a tested intervention. The registered 284 participants enrollment target is mid-sized for trials with a published cap, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (90% lower).
The record links to 1 condition, with Breast Cancer appearing as the primary indexed condition, and to 2 interventions - of which PBI Radiotherapy 6 Gy is the first listed.
NCT02276885 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT02276885 about?
NCT02276885 is a clinical study titled "Prone Partial Breast Irradiation (PBI): a Prospective Randomized Trial". The purpose of this study is to test whether a radiotherapy regimen of 8 GY x 3 days over 5 days (every other day) is as safe (well-tolerated) and effective as 6 Gy x 5 over five consecutive days
What is the current status of trial NCT02276885?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 284 participants. The study started on 2014-10-28. Estimated completion is 2026-12-07.
What conditions does trial NCT02276885 study?
This clinical trial studies the following conditions: Breast Cancer.
What interventions are being tested in trial NCT02276885?
The interventions under investigation include: PBI Radiotherapy 6 Gy (RADIATION), PBI Radiotherapy 8 Gy (RADIATION).
Who is sponsoring clinical trial NCT02276885?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02276885 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02276885's enrollment target sits among peer trials
284 295th of 1224 higher than 930 of 1,224 other Breast Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Breast Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Harnessing Analysis RNA Expression and Molecular Subtype to Optimize Novel TherapY MBCA
RECRUITING · NA
-
Post-operative Radiotherapy Omission in Selected Patients With Early Breast Cancer Trial International VErsion (PROSPECTIVE)
RECRUITING · NA
-
Resistance and Aerobic Exercise for Prevention in Women With Dense Breasts (REP-D)
RECRUITING · NA
-
Partial Breast Re-irradiation Using Ultra Hypofractionation (PRESERVE)
RECRUITING · NA
-
A Randomized Controlled Trial (RCT) to Determine the Efficacy of a Multidisciplinary CBT Based Pain Management Program for the Treatment of Aromatase Inhibitor Associated Musculoskeletal Symptoms (AIMSS) in Breast Cancer Survivors
RECRUITING · NA
-
Precise Oncology Interventions in Nutrition and Training (OnPoint)
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05263206 · 284 participants · Phase 3
Efficacy and Safety of Subcutaneous Dupilumab for the Treatment of Adult Participants With Chronic Pruritus of Unknown Origin (CPUO) (LIBERTY-CPUO-CHIC)
- NCT05769218 · 284 participants · NA
PrEP and MOUD Rapid Access for Persons Who Inject Drugs: The CHORUS+ Study
- NCT06856577 · 284 participants · Phase 3
Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-Related Macular Degeneration
- NCT06963034 · 284 participants · Phase 3
NBI-1117568-SCZ3029: Evaluation of NBI-1117568 in Inpatient Adults With Schizophrenia
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI